2023年中国手足口病疫苗行业概览

Investment Rating - The report does not explicitly provide an investment rating for the hand-foot-mouth disease vaccine industry in China Core Insights - The overall market size of the hand-foot-mouth disease vaccine industry in China is on a declining trend, with a significant drop in both disease incidence and vaccination rates [4][28] - The market size decreased from 5.05 billion yuan in 2018 to 2.67 billion yuan in 2022, with a compound annual growth rate (CAGR) of -14.7% [4][27] - It is projected that the market size will further decline from 2.47 billion yuan in 2023 to 1.83 billion yuan by 2027, with a CAGR of -7.2% [27] Summary by Sections Industry Overview - Hand-foot-mouth disease (HFMD) is primarily caused by enteroviruses such as EV71 and CVA16, and it is classified as one of the top five class B infectious diseases in China [9][11] - The disease has a high transmission rate and can lead to severe complications, making it a significant public health concern [11] Market Size - The market size of the hand-foot-mouth disease vaccine industry has shown a consistent decline, with the number of vaccine batches issued dropping from 28.06 million in 2018 to 14.85 million in 2022, reflecting a CAGR of -14.7% [28][37] - The incidence of HFMD cases decreased from 2.353 million in 2018 to 673,000 in 2022, with a CAGR of -26.9% [28][34] Vaccine Development Trends - There is a shift towards the development of multivalent vaccines due to the changing pathogen spectrum of HFMD, with increasing cases caused by non-EV71 and non-CVA16 strains [5][50] - The report highlights that only three single-component vaccines have been approved, leading to a high industry concentration with a "three-legged" competitive structure [5][65] Competitive Landscape - The industry is characterized by high concentration, with the leading companies being the Chinese Academy of Medical Sciences, Wuhan Institute of Biological Products, and Sinovac Biotech, holding market shares of 47.4%, 31.2%, and 21.4% respectively [5][72] - The report indicates that the development of new products is slow, and there are currently no significant new products expected to enter the market in the foreseeable future [67][68]